Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Signs and Symptoms 1 Psoriasis 1 Nutrition Disorders 1 Insulin Resistance 1 Inflammatory Bowel Diseases 1 Glioma 1 Glioblastoma 1 Gastroparesis 1 Feeding and Eating Disorders 1 Esophageal Neoplasms 1 Dumping Syndrome 1 Diarrhea 1 Breast Neoplasms 1 Brain Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Temozolomide 88 Bevacizumab 49 Radiotherapy 36 Irinotecan 22 Magnetic Resonance Spectroscopy 20 Surgical Procedures, Operative 17 Carboplatin 17 Carmustine 15 Radiation 13 Nivolumab 11 IL13-PE38 8 Erlotinib Hydrochloride 8 Thalidomide 7 Radiotherapy, Intensity-Modulated 7 Lomustine 7 Imatinib Mesylate 7 Everolimus 7 Aminolevulinic Acid 7 sargramostim 6 Topotecan 6 O(6)-benzylguanine 6 Cyclophosphamide 6 Chemotherapy, Adjuvant 6 vandetanib 5 temsirolimus 5 fluorodopa F 18 5 Vincristine 5 Surveys and Questionnaires 5 Radiosurgery 5 Flucytosine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Glioma × Sulfasalazine × Clear all

NCT04205357 2023-03-03

SAS-GKRS

Haukeland University Hospital

Phase 1 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡